ReviewInternational journal of molecular sciences2019
The Role of Osteoprotegerin and Its Ligands in Vascular Function.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 2 syntheses or guidelines pooled it, 147 citations in OpenAlex.
- Correlation between osteoprotegerin and coronary artery calcification in diabetic subjects: a systematic review of observational studies.BMC cardiovascular disorders · 2023Pooled it
- Osteoprotegerin SNP associations with coronary artery disease and ischemic stroke risk: a meta-analysis.Bioscience reports · 2020Pooled it
- Effects of calcitriol (1,25(OH)₂D₃) on endothelial-derived factors implicated in atheromatous plaque vulnerability.Hormones (Athens, Greece) · 2026Review
- Blood pressure, proteomic vascular ageing, and incident cardiovascular disease.European journal of preventive cardiology · 2026Article
- Picosecond laser-engineered osteon-inspired concentric micropatterns on titanium implants regulate cellular behaviour to facilitate osseointegration.Materials today. Bio · 2026Article
- Physical Exercise as a Therapeutic Approach for Patients Living with Type 2 Diabetes: Does the Explanation Reside in Exerkines?-A Review.International journal of molecular sciences · 2025Review
- Novel cardiac biomarkers and multiple-marker approach in the early detection, prognosis, and risk stratification of cardiac diseases.World journal of cardiology · 2025Review
- Plasma Proteomic Profiling Yields a High-Performance Biomarker Panel for Predicting a Poor Prognosis in Patients with COVID-19.Journal of proteome research · 2025Article
- Osteoprotegerin and its ligands RANKL and TRAIL in falciparum, vivax, and knowlesi malaria.iScience · 2025Article
- Morphometric vertebral fractures at hospitalization associate with Long COVID occurrence.Journal of endocrinological investigation · 2025Article
- Bone-derived factors mediate crosstalk between skeletal and extra-skeletal organs.Bone research · 2025Review
- Current Prognostic Biomarkers for Peripheral Arterial Disease: A Comprehensive Systematic Review of the Literature.Metabolites · 2025Review
- Article
- Beyond Bone Remodeling: Denosumab's Multisystemic Benefits in Musculoskeletal Health, Metabolism, and Age-Related Diseases-A Narrative Review.Biomedicines · 2025Review
- Association between bone mineral density and vascular health in rheumatoid arthritis.Singapore medical journal · 2025Article
- Review
- Osteoprotegerin as an Emerging Biomarker of Carotid Artery Stenosis? A Scoping Review with Meta-Analysis.Diagnostics (Basel, Switzerland) · 2025Review
- Identification of hub genes in congenital hypothyroidism and construction of the associated immune regulatory network.Frontiers in immunology · 2025Article
- Endothelial dysfunction in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: current knowledge and novel biomarkers.Frontiers in endocrinology · 2025Review
- The association between bone turnover biomarkers and the severity of white matter hyperintensities.Frontiers in neurology · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The superfamily of tumor necrosis factor (TNF) receptors includes osteoprotegerin (OPG) and its ligands, which are receptor activators of nuclear factor kappa-B ligand (RANKL) and TNF-related apoptosis-inducing ligand (TRAIL). The OPG/RANKL/RANK system plays an active role in pathological angiogenesis and inflammation as well as cell survival. It has been demonstrated that there is crosstalk between endothelial cells and osteoblasts during osteogenesis, thus establishing a connection between angiogenesis and osteogenesis. This OPG/RANKL/RANK/TRAIL system acts on specific cell surface receptors, which are then able to transmit their signals to other intracellular components and modify gene expression. Cytokine production and activation of their receptors induce mechanisms to recruit monocytes and neutrophils as well as endothelial cells. Data support the role of an increased OPG/RANKL ratio as a possible marker of progression of endothelial dysfunction in metabolic disorders in relationship with inflammatory marker levels. We review the role of the OPG/RANKL/RANK triad in vascular function as well as molecular mechanisms related to the etiology of vascular diseases. The potential therapeutic strategies may be very promising in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.